Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Reck

Showing results (61-70 of 114) with videos related to

Pageof 12
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2020
Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"D Planchard, S Popat, K Kerr, et al.
Pneumologie (Stuttgart, Germany)|January 19, 2011
[Joint statement of the German Respiratory Society and the German Roentgenological Society on the early detection of lung cancer by low-dose CT]C Vogelmeier, H Worth, M Pfeifer, et al.
Lung Cancer (Amsterdam, Netherlands)|February 25, 2014
Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancerD F Heigener, K M Deppermann, J V Pawel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2016
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upS Novello, F Barlesi, R Califano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2018
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upD Planchard, S Popat, K Kerr, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2023
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upL E Hendriks, K M Kerr, J Menis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 20, 2023
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upL E Hendriks, K M Kerr, J Menis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2014
A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancerA A Chiappori, T Kolevska, D R Spigel, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2004
Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trialC Gridelli, C Manegold, P Mali, et al.
ESMO Open|June 30, 2023
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing resultsE B Garon, M Reck, K Nishio, et al.
Pageof 12

Showing results (61-70 of 114) with videos related to

Sort By:
Pageof 12
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2020
Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"D Planchard, S Popat, K Kerr, et al.
Pneumologie (Stuttgart, Germany)|January 19, 2011
[Joint statement of the German Respiratory Society and the German Roentgenological Society on the early detection of lung cancer by low-dose CT]C Vogelmeier, H Worth, M Pfeifer, et al.
Lung Cancer (Amsterdam, Netherlands)|February 25, 2014
Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancerD F Heigener, K M Deppermann, J V Pawel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2016
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upS Novello, F Barlesi, R Califano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2018
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upD Planchard, S Popat, K Kerr, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2023
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upL E Hendriks, K M Kerr, J Menis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 20, 2023
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upL E Hendriks, K M Kerr, J Menis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2014
A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancerA A Chiappori, T Kolevska, D R Spigel, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2004
Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trialC Gridelli, C Manegold, P Mali, et al.
ESMO Open|June 30, 2023
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing resultsE B Garon, M Reck, K Nishio, et al.
Pageof 12